Individualizing Injectable Testosterone Replacement Therapy in Primary Care: Pharmacokinetics, Symptom Stability, Safety Monitoring, and Injection Frequency.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review and expert commentary without systematic search methodology or original experimental data.
PubMed 42292725 · doi:10.7759/cureus.110570
What was done
The authors conducted a narrative clinical review outlining strategies for primary care clinicians to individualize injection intervals and dosing regimens for short-acting injectable testosterone esters, such as testosterone cypionate and enanthate, in men with confirmed hypogonadism.
What was found
The abstract reports no quantitative outcome data or statistical comparisons. It describes that short-acting esters can produce wide pharmacokinetic fluctuations when dosed every two weeks, potentially leading to peak-related adverse effects and trough-related symptom recurrence. It proposes that weekly dosing is often an effective baseline, while split-dose regimens (such as twice-weekly or more frequent injections) serve as clinical options to smooth exposure without necessarily increasing the total weekly dose.
Why it matters
This paper provides practical guidance for primary care clinicians managing testosterone replacement therapy, emphasizing pharmacokinetic timing and dose redistribution over simple dose escalation to stabilize symptoms and improve safety monitoring.
Limits
The paper is a non-systematic narrative review providing expert commentary and clinical reasoning rather than primary trial data or systematic synthesis. No specific sample size, quantitative efficacy metrics, or direct comparative safety data are reported in the abstract.
Cited by
- context Infrequent testosterone injections drive down sex hormone-binding globulin (SHBG) levels proportionally, leading to disproportionately high free testosterone.